No we don't. The company's future doesn't hinge on PC data. Their lead candidate is still AML. Everyone wants to believe the company they are invested in is going to be bought out. The pancreatic data is literally the first readout from the trial. All indications point to it being good but to assume we are going to be bought out once it's released is pure speculation and wishful thinking. Until there is a PR saying that MRKR was bought out then there is no reason to speculate on it.
News 
Market Data 
Discover 
